Nuo Therapeutics Reports Full-Year 2014 Financial Results

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Nuo Therapeutics Reports Full-Year 2014 Financial Results

GAITHERSBURG, Md., March 31, 2015 (GLOBE NEWSWIRE) -- Nuo Therapeutics, Inc. (OTCQX:NUOT) a pioneer in biodynamic therapies, today reported financial results for the year ended December 31, 2014.

2014 and Recent Corporate Highlights

  • Implemented a series of strategic initiatives to reposition Nuo as a pure-play chronic wound care company
  • Completed corporate name change to Nuo Therapeutics; re-launched chronic wound care system under Aurix™ brand
  • Completed $35 million convertible debt financing with Deerfield Management Company to support implementation of commercial strategy
  • Discontinued ALD-401 Bright Cell development program and closed research & development facility in Durham, NC
  • Signed exclusive licensing and distribution agreement with Rohto Pharmaceutical Co. to develop and commercialize Aurix in Japan
  • Initiated post-market study (the "Au Study") of Aurix under Centers for Medicare and Medicaid Services (CMS) Coverage with Evidence Development (CED) Program

Full-year 2014 Financial Summary

  • Total revenues were $7.8 million, compared with $11.6 million in 2013
  • Net loss was $18.9 million, or $0.16 per share, compared with $20.2 million, or $0.20 per share in 2013
  • Cash and cash equivalents totaled approximately $15.9 million as of December 31, 2014

Fourth Quarter 2014 Financial Summary

  • Total revenues were $1.9 million, compared with $3.5 million in the fourth quarter of 2013
  • Net income of $2.9 million, compared with a net loss of $4.9 million in the fourth quarter of 2013. Fourth quarter 2014 net income included an unrealized non-cash gain related to change in fair value of derivative liabilities totaling $8.3 million, compared with an unrealized non-cash charge of $0.7 million in the same period of 2013.

"2014 was a year in which we made significant progress toward implementing our commercial strategy and established the necessary foundation for sustainable long-term growth," said Martin Rosendale, Chief Executive Officer of Nuo Therapeutics.

"Our results for the year reflect several key initiatives aimed at establishing Nuo as an emerging leader in individualized wound care. These include building a world-class commercial organization, the discontinuation of the ALD-401 R&D program and an ongoing transition of the Angel® system to Arthrex following our 2013 licensing agreement, which allow us to focus on maximizing our commercial efforts around launching Aurix as a best-in-class wound care system. We are aware however of the need for scale in optimizing sales force efficiency in the wound care space, and we have, from time to time in the past, actively explored strategic and product-related opportunities. We continue to investigate opportunities that we believe could optimize our commercial infrastructure, broaden our business and increase shareholder value while positioning the Company for long-term success in the changing wound care environment.

"Thus far in 2015, we have continued to steadily advance the Aurix commercial program through CMS approval of our amended CED protocols and initiation of our Au Study. These recent milestones give us confidence in our ability to take advantage of the large chronic wound care market opportunity, and we anticipate that the substantial efforts we have put forth have the potential to generate meaningful returns over time."

Since initiating the Au Study in February 2015, the Company has implemented the revised CED data collection protocols at several outpatient facilities and begun enrolling patients into the registry. Nuo is also collaborating with spinal cord injury units and wound care centers at Veterans Administration (VA) hospitals who are evaluating the product on a sample basis. Three such sites are currently in the final stages of product evaluation, while a number of other facilities have initiated the review process and are expected to advance to product evaluation in the coming months.

Dean Tozer, Chief Commercial Officer of Nuo Therapeutics, added: "In the five months since we launched the newly-branded Aurix at the Symposium on Advanced Wound Care (SAWC) Fall Meeting, our commercial team has been aggressively pursuing a variety of sales opportunities with customer targets, focusing on those responsible for making purchasing decisions at Veterans Administration hospitals and outpatient wound care centers. We have made excellent progress and have overcome a number of challenges to reach this point. I am proud of what our team has accomplished and their work to get us to where we are today, and I remain confident that our greatest success is yet to come."

Financial Results for the Year Ended December 31, 2014

Total revenues for the year were $7.8 million, compared to $11.6 million in 2013. The year-over-year decline in total revenues was primarily related to decreases in product sales and service revenue, partially offset by increased royalties and license fee revenue. Full-year gross margin was 13%, compared with 27% in 2013. The gross margin decrease was attributable to Angel disposable products, which were sold to Arthrex at a lower average selling price in 2014 as compared to the prior year. In addition we recognized increased costs related to actual and expected Angel centrifuge refurbishment costs and an inventory reserve established for excess and obsolete inventory. This was partially offset by an increase in gross profit and margin from Angel related license fees and royalty revenue.

Total operating expenses for the year were $24.4 million, compared to $21.2 million in 2013. The increase in operating expenses was attributable to the expansion of Nuo's commercial, marketing, and clinical organization, as well as a non-cash impairment charge for in process research and development. This was partially offset by reduced expenses following the closure of the Company's research and development facility in North Carolina.

The Company reported a net loss for the year of $18.9 million, or $(0.16) per share, compared with $20.2 million or $(0.20) per share a year ago.

Cash and cash equivalents as of December 31, 2014 totaled approximately $15.9 million, compared with approximately $3.3 million as of December 31, 2013.

Financial Results for the Fourth Quarter Ended December 31, 2014

Total revenues were $1.9 million in the fourth quarter, compared to $3.5 million in the same period of 2013. The decrease was primarily due to a reduction in Angel disposable product sales to Arthrex, partially offset by an increase in royalty revenue as a result of increased sales by Arthrex. Gross margin in the fourth quarter of 2014 was (10%), compared with 14% in the fourth quarter of 2013. The negative gross margin in the fourth quarter of 2014 was attributable primarily to increased costs related to actual and expected Angel centrifuge refurbishment costs and an inventory reserve established for excess and obsolete inventory. This was partially offset by an increase in gross profit and margin from Angel related license fees and royalty revenue. Total operating expenses in the fourth quarter were $4.2 million, compared to $4.3 million in the same period of 2013.

Net income in the fourth quarter was $2.9 million, compared to a net loss of $4.9 million in the fourth quarter of 2013. Fourth quarter 2014 net income included an unrealized non-cash gain related to the change in fair value of derivative liabilities totaling $8.3 million. This compares to an unrealized non-cash charge of $0.7 million in the fourth quarter of 2013.

Conference Call and Webcast:

Wednesday, April 1, 2015 @ 8am Eastern/5am Pacific   Replays – Available through April 8, 2015
Domestic: 877-407-4018   Domestic: 877-870-5176
International: 201-689-8471   International: 858-384-5517
Passcode: 13604618   Passcode: 13604618
Webcast: www.nuot.com    

About Nuo Therapeutics

Nuo Therapeutics, Inc. (the "Company") is a biomedical company that pioneers leading-edge biodynamic therapies for wound care. The Company's flagship product, Aurix is a biodynamic hematogel that harnesses a patient's innate regenerative abilities for the management of a variety of wounds. For additional information please visit www.nuot.com .

About Aurix

Aurix is the first platelet and plasma therapy system to be cleared by FDA for the management of a broad range of ulcers and exuding wounds, including:

  • All types (diabetic foot ulcer, venous leg ulcer, pressure ulcer, etc.),
  • All morphologies (partial thickness, full thickness and complex wounds),
  • All severities (tunneling, sinus tract, bone, tendon and hardware exposure).

Unlike other cellular-based treatment options, Aurix is an autologous biodynamic hematogel that is derived from a patient's own platelets and plasma. The product is used at the point-of-care to stimulate the natural wound healing process from deep within the wound bed. For additional information, please visit www.AurixSystem.com .

Safe Harbor Statement -- This press release contains "forward-looking statements" pursuant to the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, without limitation, any statement that may predict, forecast, indicate, or imply future results, performance or achievements, and may contain the words "believes", "forecasted," "projects," "is expected," "remain confident," "will", "estimate," "target," "plan," "should", "would," "is likely," "may," and/or similar expressions. The information contained in the forward-looking statements, including without limitation those about the Company's estimated revenue, gross margin, operating expenses and other income or expenses, is inherently uncertain, and the Company's actual results may differ materially from these forward-looking statements.   These forward-looking statements include, without limitation, statements concerning the Company's ability to successfully launch and rebrand its wound care system in the timeframe and to the extent anticipated, the Company's ability to estimate the potential of the wound care market and to commercialize any of its rebranded products / therapies, successfully execute its Aurix (formerly AutoloGel) sales and commercialization strategies, the Company's ability to launch Aurix as expected and derive financial and commercial benefits of such launch, to achieve Aurix expected reimbursement rates in 2015 and thereafter, the Company's ability to comply with the debt covenants and restrictions under its existing loan facilities, the Company's ability to realize expected benefits from the Arthrex licensing arrangement, the Company's ability to collect the data necessary for the grant of the unconditional coverage, the Company's ability to continue in its efforts to expand in the wound care market, and its ability to successfully negotiate with physician offices as anticipated and to realize the anticipated sales growth from such treatment. Forward-looking statements are also subject to many risks and uncertainties that could cause our actual results and the timing of certain events to differ materially from any future results expressed or implied by the forward-looking statements, including, but not limited to, risks as to whether the Company may achieve a favorable CMS determination relating to the reimbursement rates for Aurix, the Company's ability to successfully realize sales of the Angel Technology resulting in the royalty stream to the Company, the Company's ability to expand patient populations as contemplated, its ability to provide Medicare patients with access as expected, the Company's ability to realize its expectations of favorable future dialogue with potential strategic partners, its ability to identify, proceed with and consummate strategic initiatives , its ability to successfully manage contemplated clinical trials, its ability to manage and address the capital needs, human resources, management, compliance and other challenges of a larger, more complex and integrated business enterprise, the viability and effectiveness of the Company's sales approach and overall marketing strategies, its ability to secure Medicare reimbursements at adequate levels; its ability to realize commercial success or acceptance by the medical community, the Company's ability to raise additional capital or issue additional securities and to continue as a going concern, and the Company's ability to execute on its strategy to market the Aurix System as contemplated, and other risks and uncertainties described in our filings with the U.S. Securities and Exchange Commission, including the most recent reports on Forms 10-K, 10-Q and 8-K, and any amendments thereto. Undue reliance should not be placed on forward-looking information. Nuo Therapeutics operates in a highly competitive and rapidly changing business and regulatory environment, thus new or unforeseen risks may arise. Except as is expressly required by the federal securities laws, Nuo Therapeutics undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, changed circumstances or future events or for any other reason.

Nuo Therapeutics, Inc. 
Consolidated Statements of Operations
         
  Three Months Ended
December 31,
Year Ended
December 31,
  2014 2013 2014 2013
  (UNAUDITED) (UNAUDITED) (AUDITED) (AUDITED)
Revenues        
Product sales $ 1,374,360 $ 2,956,852 $ 5,849,330 $ 10,498,726
License fees 100,481 100,594 402,264 167,657
Royalties 423,033 334,098 1,510,340 703,744
Other revenue -- 72,476 -- 201,311
Total revenues 1,897,874 3,464,020 7,761,934 11,571,438
         
Cost of revenues        
Cost of sales 2,041,689 2,924,501 6,594,006 8,363,902
Cost of royalties 44,194 47,712 176,737 89,290
Total cost of revenues 2,085,883 2,972,213 6,770,743 8,453,192
Gross profit (188,009) 491,807 991,191 3,118,246
         
Operating expenses        
Salaries and wages 2,253,125 1,308,070 8,473,427 7,319,407
Consulting expenses 26,765 552,407 1,401,381 2,148,983
Professional fees 286,350 329,670 1,221,462 1,156,868
Research, development, trials and studies 75,982 748,360 2,623,541 3,798,398
General and administrative expenses 1,590,729 1,373,892 5,978,429 6,789,660
Impairment of trademarks and IPR&D -- -- 4,683,829 --
Total operating expenses 4,232,951 4,312,399 24,382,069 21,213,316
Loss from operations (4,420,960) (3,820,592) (23,390,878) (18,095,070)
         
Other income (expense)        
Interest, net (847,417) (356,123) (3,434,783) (1,680,023)
Change in fair value of derivative liabilities 8,259,553 (720,401) 8,100,922 (470,052)
Loss on disposal of fixed assets (131,456) -- (131,456) --
Other 1,791 3,043 (7,493) 15,374
Total other income (expenses) 7,282,471 (1,073,481) 4,527,190 (2,134,701)
Loss before provision for income taxes 2,861,511 (4,894,073) (18,863,688) (20,229,771)
Income tax provision 5,649 3,919 19,584 18,589
Net loss 2,855,862 (4,897,992) (18,883,272) (20,248,360)
         
Loss per common share --        
Basic and diluted      $ (0.16)  $ (0.20)
         
Weighted average shares outstanding --        
Basic and diluted     120,516,225 103,620,046
 
Nuo Therapeutics, Inc. 
Consolidated Balance Sheets
     
  December 31,
2014
December 31,
2013
  (AUDITED) (AUDITED)
ASSETS    
     
Current assets    
Cash and cash equivalents $ 15,946,425 $ 3,286,713
Short-term investments, restricted 53,391 53,257
Accounts and other receivable, net 1,889,327 3,926,681
Inventory, net 556,620 1,111,507
Prepaid expenses and other current assets 2,338,990 1,258,282
Deferred costs, current portion 1,091,387 316,551
Total current assets 21,876,140 9,952,991
     
Property and equipment, net 925,171 919,469
Deferred costs 3,547,007 482,349
Intangible assets, net 28,747,770 33,768,954
Goodwill 1,128,517 1,128,517
Total assets $ 56,224,605 $ 46,252,280
     
     
LIABILITIES AND STOCKHOLDERS' EQUITY    
     
Current liabilities    
Accounts payable $ 1,877,736 $ 3,351,844
Accrued expenses 6,218,224 4,666,828
Deferred revenues, current portion 402,377 740,990
Note payable, current portion -- 1,800,000
Total current liabilities 8,498,337 10,559,662
     
Notes payable -- 3,620,593
Convertible debt, net of debt discount 325,553 202,658
Deferred revenues 1,039,475 1,441,852
Derivative liabilities 29,846,821 3,248,595
Other liabilities 546,867 366,926
Total liabilities 40,257,053 19,440,286
     
Conditionally redeemable common stock (909,091 issued and outstanding) 500,000 500,000
     
Stockholders' equity    
Common stock; $.0001 par value, authorized 425,000,000 shares;    
2014 issued and outstanding - 125,680,100 shares;    
2013 issued and outstanding - 107,164,855 shares 12,477 10,626
Common stock issuable 392,950 432,100
Additional paid-in capital 125,173,973 117,097,844
Accumulated deficit (110,111,848) (91,228,576)
Total stockholders' equity 15,467,552 26,311,994
Total liabilities and stockholders' equity $ 56,224,605 $ 46,252,280

Nuo Therapeutics, Inc. Martin Rosendale, CEO Steven Shallcross, EVP/ CFO 240-499-2680 Investors: The Ruth Group Lee Roth 646-536-7012

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Automus and Google Cloud Put Agents to Work on Oracle

Updated Category News Views 96

Oracle back offices are where shiny AI promises go to earn their keep, or get buried under a mountain of integrations. Automus Consulting’s newly announced collaboration with Google Cloud, unveiled November 20 at Oracle AI World, is aimed squarely at that messy middle. The firm wants to combine its Oracle implementation experience with Google Cloud infrastructure and...

Continue Reading
PayPal Adds a Risk Hand to Its Board at a Crucial Turn

Updated Category News Views 91

A Boardroom Hire With Some Actual Weight PayPal did not go hunting for another decorative résumé. Brian J. Lee, set to join the board on November 30, 2026, spent decades inside Goldman Sachs, including a stint as chief risk officer from 2019 through January 2025. For a payments company trying to sharpen its financial-services identity, that is a serious piece of...

Continue Reading
S&P Global's UBS AI Conference Slot Deserves Attention

Updated Category News Views 88

Thirty Minutes Can Still Matter A half-hour fireside chat is not a quarterly earnings call, and anybody treating it like one is setting themselves up for disappointment. Still, S&P Global CEO Martina Cheung appearing at the UBS Global Technology and AI Conference on December 2 deserves a spot on the calendar for owners of NYSE:SPGI. This is a company sitting in the middle...

Continue Reading
Danaher and Microsoft Put AI Into the Lab Stack Early

Updated Category News Views 103

Laboratory AI gets interesting only when it reaches the hardware bench, and Danaher is taking a serious swing at that ugly, complicated job with Microsoft. The Nov. 20 partnership is not just another chatbot bolted onto a dashboard. It is aimed at building a common agentic platform that can help instruments interpret scientific intent, guide setup, control hardware within...

Continue Reading
YPTC’s Florida Office Bets on Nonprofit Finance Needs

Updated Category News Views 50

A Local Flag Planted After Years of Work Florida nonprofits do not need another consultant waving a glossy slide deck around; they need clean books, grant compliance, and somebody who can tell them where the cash is going before the lights start blinking red. That is the practical opening YPTC is chasing with a Jacksonville-based Florida office, its sixteenth office...

Continue Reading
Duetti, CesiumAstro, and a Busy NYSE Capital Morning

Updated Category News Views 78

Three very different piles of money are jamming up the November 20 NYSE slate, and that contrast is the whole point. Private music catalogs, space-and-defense communications, and a new stock-and-bond ETF do not belong in the same bucket. Yet all three are competing for investor attention before the opening bell, alongside Danaos Corporation's 20th listing anniversary....

Continue Reading
RLX Revenue Soars, but European Margins Need Proof

Updated Category News Views 111

Revenue can wear a fancy suit while earnings arrive in work boots, and RLX Technology's third quarter is exactly that kind of report. The newly consolidated European distribution business pushed third-quarter revenue to RMB1.92 billion, up 69.7% year over year. That is a real jump, not pocket change. But the same acquisition also changed the mix, squeezed the blended...

Continue Reading
Neurelis Founder Earns EY's 2026 Top Entrepreneur Honor

Updated Category News Views 65

Some business awards are wallpaper; this one carries real clinical weight. EY US named Craig Chambliss, CEO and co-founder of Neurelis, its Entrepreneur Of The Year 2026 National Overall Award winner. In a sector where plenty of companies talk grandly about changing lives and then vanish into the regulatory fog, the underlying story matters more than the trophy. Neurelis...

Continue Reading
RingConn Bets Middle-earth Fandom Can Boost Health Wearables

Updated Category News Views 102

A Familiar Gold Band Meets a Crowded Wearables Market RingConn has taken one of pop culture's most loaded objects and turned it into a health-tracking accessory, which is either clever brand work or a costly bit of cosplay depending on execution. The company unveiled The One Ring, a limited-edition version of its Gen 3 Smart Ring, through a partnership with Warner Bros....

Continue Reading
D-Wave Investors Face December 15 Lead Plaintiff Clock

Updated Category News Views 94

Quantum dreams met a very earthly spreadsheet problem at D-Wave this summer. The proposed securities class action against D-Wave Quantum Inc. puts a hard date on the issue for investors who bought shares between February 26 and August 25, 2026: December 15, 2026 is the deadline to seek lead-plaintiff status. That does not mean every holder needs to march into court. It...

Continue Reading

Top 5 Most Recently Viewed Articles

Innovative Weight Loss Solutions: ASC36 and ASC35 Development

Updated Category News Views 312

Exciting Co-formulation Advancements by Ascletis Pharma Ascletis Pharma Inc. has made a significant stride in obesity treatment with the co-formulation of ASC36, a monthly amylin receptor agonist, and ASC35, a GLP-1R/GIPR dual agonist. These innovative therapies aim to offer better patient outcomes through advanced pharmacokinetic profiles and a robust efficacy in weight...

Continue Reading
Schouw & Co. Reports Steady Q1 Performance Amidst Challenges

Updated Category News Views 291

Overview of Q1 2025 Performance Recently, Schouw & Co. disclosed their interim report for the first quarter of 2025, highlighting a performance that generally met expectations despite ongoing economic turbulence. While the disturbances in the market have generated caution among customers, the direct effects on Schouw & Co.'s operations seem to have been minimal. Key...

Continue Reading
Parker Hannifin to Present at Jefferies Industrials Conference

Updated Category News Views 153

Parker Hannifin Set to Present at the Jefferies Industrials Conference Parker Hannifin Corporation (NYSE: PH), a recognized leader in motion and control technologies worldwide, has announced its participation in the prestigious Jefferies Industrials Conference. This important event will take place in early September, bringing together industry leaders and innovators to...

Continue Reading
374Water Innovatively Enhances Waste Management Solutions

Updated Category News Views 121

Revolutionizing Waste Management with AirSCWO Technology DURHAM, N.C. – 374Water Inc. (NASDAQ: SCWO) is making significant advancements with its innovative AirSCWO technology aimed at revolutionizing waste management practices. The Company has partnered with the Orange County Sanitation District (OC San) to implement its cutting-edge AirSCWO 6 System at their treatment...

Continue Reading
SharpLink Gaming Expands Footprint in Crypto Gaming Market

Updated Category News Views 548

SharpLink Gaming Advances in Crypto Gaming with Strategic Investment SharpLink Gaming, Inc. (NASDAQ: SBET), a notable player in online marketing for sports betting and iGaming, has declared an exciting venture that marks its entry into the rapidly growing crypto gaming sector. Recently, the company secured a 10% equity stake in Armchair Enterprises, the parent company of...

Continue Reading